文献速递胸部肿瘤放疗放疗物理与技术

肿瘤位置与剂量学预测因素对Ⅰ期非小细胞肺癌单次分割立体定向体部放疗胸壁毒性的影响

Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
PubMed 文献 · Pract Radiat Oncol · 2018-12-07

该研究基于1462例前瞻性登记数据库,分析146个接受30 Gy或34 Gy单次分割立体定向体部放疗的Ⅰ期非小细胞肺癌病灶,评估肿瘤位置与剂量学参数与胸壁毒性的关系。结果显示肿瘤紧贴胸壁者2-4级胸壁毒性发生率为30.6%,多因素分析中肿瘤紧贴胸壁为胸壁毒性的显著预测因素(OR 7.5,P=0.007)。作者认为肿瘤位置不是单次分割立体定向体部放疗的禁忌证,但紧贴胸壁时胸壁毒性发生率显著增加。

要点

  • 146个病灶中2-4级胸壁毒性总发生率为:紧贴胸壁30.6%、距胸壁≤1 cm 8.2%、1-2 cm 3.8%、>2 cm 5.7%。
  • 3级及以上胸壁毒性发生率为1.4%。
  • 多因素分析显示肿瘤紧贴胸壁是胸壁毒性的显著预测因素(OR 7.5,P=0.007)。

核心结论

  • 单次分割立体定向体部放疗的胸壁毒性发生率与已发表的分割立体定向体部放疗相似,且大多数胸壁毒性为低级别。
  • 肿瘤相对于胸壁的位置不是单次分割立体定向体部放疗的禁忌证,但紧贴胸壁时胸壁毒性发生率显著增加。
  • 肋骨D1cc及胸壁D1cc和D5cc可作为胸壁毒性的预测因素。

研究设计与样本

  • 研究基于1462例患者的前瞻性登记数据库,纳入接受30 Gy或34 Gy单次分割立体定向体部放疗的146个病灶。
  • 肿瘤与胸壁的关系分为紧贴、≤1 cm、1-2 cm和>2 cm四类。
  • 胸壁毒性按不良事件通用术语标准3.0版前瞻性分级,2级需药物治疗,3级需操作干预,4级为致残性疼痛,1级胸壁毒性或影像学肋骨骨折未纳入。
  • 采用逻辑回归分析识别与胸壁毒性相关的参数并计算胸壁毒性概率。

主要发现

  • 中位随访时间为23.8个月。
  • 5年局部控制率、远处转移率和总生存率分别为91.8%、19.2%和28.7%。
  • 2-4级胸壁毒性发生率:紧贴胸壁病灶为30.6%,距胸壁≤1 cm为8.2%,距胸壁1-2 cm为3.8%,距胸壁>2 cm为5.7%。
  • 3级及以上胸壁毒性发生率为1.4%。
  • 单因素分析中,肿瘤紧贴胸壁(OR 6.5,P=0.0005)、体重指数(OR 1.1,P=0.02)、肋骨D1cc(OR 1.01/Gy,P=0.03)、胸壁D1cc(OR 1.08/Gy,P=0.03)和胸壁D5cc(OR 1.10/Gy,P=0.01)为胸壁毒性的显著预测因素;多因素分析中肿瘤紧贴胸壁显著(OR 7.5,P=0.007)。

关键数值与推荐

  • 胸壁毒性分级采用不良事件通用术语标准3.0版:2级需药物治疗,3级需操作干预,4级为致残性疼痛。
  • 胸壁D5cc为27.2 Gy且肋骨D1cc为30.2 Gy时,胸壁毒性概率为15%。

临床怎么用

  • 作者认为肿瘤相对于胸壁的位置不是单次分割立体定向体部放疗的禁忌证。
  • 作者认为肋骨D1cc及胸壁D1cc和D5cc可作为胸壁毒性的预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dosimetric parameters to limit chest wall toxicity (CWT) are not well defined in single-fraction (SF) stereotactic body radiation therapy (SBRT) phase 2 trials. We sought to determine the relationship of tumor location and dosimetric parameters with CWT for SF-SBRT. METHODS AND MATERIALS: From a prospective registry of 1462 patients, we identified patients treated with 30 Gy or 34 Gy. Gross tumor volume was measured as abutting, ≤1 cm, 1 to 2 cm, or >2 cm from the chest wall. CWT was prospectively graded according to Common Terminology Criteria for Adverse Events version 3.0, with grade 2 requiring medical therapy, grade 3 requiring procedural intervention, and grade 4 being disabling pain. Grade 1 CWT or radiographic rib fracture was not included. Logistic regression analysis was used to identify the parameters associated with CWT and calculate the probability of CWT with dose. RESULTS: This study included 146 lesions. The median follow-up time was 23.8 months. The 5-year local control, distant metastasis, and overall survival rates were 91.8%, 19.2%, and 28.7%, respectively. Grade 2 to 4 CWT was 30.6% for lesions abutting the chest wall, 8.2% for ≤1 cm from the chest wall, 3.8% for 1 to 2 cm from the chest wall, and 5.7% for >2 cm from the chest wall. Grade ≥3 CWT was 1.4%. Tumor abutment (odds ratio [OR]: 6.5; P = .0005), body mass index (OR: 1.1; P = .02), rib D1cc (OR: 1.01/Gy; P = .03), chest wall D1cc (OR: 1.08/Gy; P = .03), and chest wall D5cc (OR: 1.10/Gy; P = .01) were significant predictors for CWT on univariate analysis. Tumor abutment was significant for CWT (OR: 7.5; P = .007) on multivariate analysis. The probability of CWT was 15% with chest wall D5cc at 27.2 Gy and rib D1cc at 30.2 Gy. CONCLUSIONS: The rate of CWT with SF-SBRT is similar to the rates published for fractionated SBRT, with most CWT being low grade. Tumor location relative to the chest wall is not a contraindication to SF-SBRT, but the rates increase significantly with abutment. Rib D1cc and chest wall D1cc and D5cc may be used as predictors of CWT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Manyam BV, Videtic GMM, Verdecchia K, et al. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2018. PMID: 30529796. doi:10.1016/j.prro.2018.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。